Navigation Links
Breast Cancer Patients and Families Stand Up To FDA
Date:6/24/2011

SILVER SPRING, Md., June 24, 2011 /PRNewswire/ -- Breast cancer patients and their families will rally together on Tuesday, June 28, at 7:00 am outside of the Federal Drug Administration (FDA).  At issue will be the FDA's final hearing to remove the anti-cancer drug Avastin from the approved medication list for treatment of late stage breast cancer, despite the FDA approving it in 2008 for use to treat breast cancer.

Terry Kalley, founder of the Freedom of Access to Medicines (FAMEDS), will lead the protest and then testify at the morning FDA hearing on behalf of his wife.  Following the FDA hearing, the group will make its way to Capitol Hill for congressional meetings, and wrap up the day with a media availability at 1:30 pm in 2103 Rayburn House Office Building.

"It is devastating enough to know that death will come early for these women from an incurable disease, but it is outrageous and unbelievably callous of FDA bureaucrats to compound this anguish," Kalley said.  "All we are asking for is for the federal government to stay out of our medical lives and allow my wife to continue taking this drug that is prolonging her life and the lives of many others."

At the June 28 hearing, the FDA will likely reverse its previous decision to allow Avastin to be used by breast cancer patients.  The FDA will likely cite dangerous side effects, but as Kalley pointed out, "For many breast cancer patients, including my wife, the most dangerous risk is the unavailability of Avastin."

Kalley warned that when government begins to pick winners and losers, a slippery slope towards rationing medications can happen. "Today, it's Avastin for metastatic breast cancer, tomorrow it could be the drug that your loved one needs to stay alive," he said.

He concluded with a call to action, saying "Attend our rally on the 28th, sign our online petition, and write your federal representatives and senat
'/>"/>

SOURCE Freedom of Access to Medicines (FAMEDS)
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Xeloda XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium
3. Xeloda(R) XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium
4. Kosans Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial
5. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
6. Peregrine Pharmaceuticals Submits Clinical Protocol to Initiate Bavituximab Phase II Trial in Patients With Metastatic Breast Cancer
7. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
8. New Study Demonstrates 4 Year Olds Fed Enfamil LIPIL(R) as Infants Have Brain and Eye Outcomes Similar to Breastfed Babies
9. Symbollon Pharmaceuticals, Inc. Evaluates the Clinical Effects of IoGen(TM) on Fibrocystic Breast Disease
10. Spit for the Cure Offers Unique Opportunity for Women to Participate in Breast Cancer Research
11. Genomic Health Announces Preliminary Results From a Study of Oncotype DX(TM) in Node-Positive Breast Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... and TORONTO ... Corporation ( www.generex.com ) (OTCQB: GNBT) today ... implement a buccal cannabis co-development arrangement with ... been formalized. Generex and CannScience ... Technology Licensing Agreement.  Pursuant to the Agreement, ...
(Date:9/2/2015)... , Sept. 2, 2015  MGC Diagnostics Corporation ... a conference call to discuss its financial results for ... 2015. The call will be at 4:30 p.m. ET ... financial results for the third quarter of fiscal 2015 ... Participants can dial (877) 317-6789 or ...
(Date:9/2/2015)... EVANSTON, Ill. , Sept. 2, 2015 ... and a frenzy of health care M&A activity – ... place moderate-to-severe access restrictions on pharmaceutical sales reps. This ... who limit access has crossed the halfway point, according ... global sales and marketing firm ZS . ...
Breaking Medicine Technology:Generex Announces Formalization of Buccal Cannabis Co-Development Plan 2Generex Announces Formalization of Buccal Cannabis Co-Development Plan 3MGC Diagnostics Corporation to Report Third Quarter Fiscal 2015 Financial Results on Thursday, September 10, 2015 2Crossing the threshold: More than half of physicians restrict access to sales reps 2Crossing the threshold: More than half of physicians restrict access to sales reps 3Crossing the threshold: More than half of physicians restrict access to sales reps 4Crossing the threshold: More than half of physicians restrict access to sales reps 5
... 10 Ferring Pharmaceuticals today announced an ... portfolio with the acquisition of the global rights ... non-hormonal therapy indicated specifically for treatment of women ... will initially market LYSTEDA in the U.S., and ...
... , May 7 Young Innovations, Inc. (Nasdaq: YDNT ) today ... per share, payable June 15, 2010 to all shareholders of record on ... , The Company also ... Mr. McKey joined the Company in November 2003 . He has assumed positions ...
Cached Medicine Technology:Ferring Acquires LYSTEDA(TM) From Xanodyne Pharmaceuticals, Inc. 2Ferring Acquires LYSTEDA(TM) From Xanodyne Pharmaceuticals, Inc. 3Ferring Acquires LYSTEDA(TM) From Xanodyne Pharmaceuticals, Inc. 4Ferring Acquires LYSTEDA(TM) From Xanodyne Pharmaceuticals, Inc. 5Young Innovations, Inc. Board of Directors Declares Quarterly Dividend and Announces Election of New Officer 2
(Date:9/2/2015)... ... ... On September 9, 2015, over 27,000 people from all over the world ... date for the state of Utah. , “We are thrilled with the overwhelming response ... doTERRA CEO. “One of the most exciting elements of our convention is the opportunity ...
(Date:9/2/2015)... ... September 02, 2015 , ... ... Brain Aneurysm Awareness Month , which was established by the Foundation in ... awareness and education, and helping fund more research remains our top priority,” commented ...
(Date:9/2/2015)... ... ... Mobile working is increasingly more important, as business professionals are looking to be ... being launched, and mobile device usage as a whole is something people around the ... lives. What's more people are expecting mobile versions of their favorite software. , While ...
(Date:9/1/2015)... ... September 01, 2015 , ... September is National Prostate ... that affects more than 233,000 men each year in the United States. , Prostate ... common non-skin cancer in America, affecting 1 in 7 men. One new case occurs ...
(Date:9/1/2015)... Los Angeles, CA (PRWEB) , ... September 01, 2015 , ... ... the American Medical Association, individuals with type 2 diabetes that participated in a three ... of diabetes three years down the line if they elected weight loss surgery at ...
Breaking Medicine News(10 mins):Health News:doTERRA to Host the Largest Single-Company Convention in the State of Utah 2Health News:September Celebrated as Brain Aneurysm Awareness Month 2Health News:New Mobility Experience From Winscribe 2Health News:New Mobility Experience From Winscribe 3Health News:September is Prostate Cancer Awareness Month 2Health News:September is Prostate Cancer Awareness Month 3Health News:Recent Journal Article on Diabetes Remission Adds to the Growing Pile Of Evidence in Favor of Bariatric Surgery, Says Dr. Feiz and Associates 2
... cells continue to flow to newborn in minutes after birth, ... women may want to consider asking their doctors to hold ... after the baby is born, a new study suggests. , ... the blood flow from mom to baby. While not necessarily ...
... experts say , WEDNESDAY, May 26 (HealthDay News) -- Malignant ... tens of thousands of genetic mutations which, together, contribute to ... lung tumor from a heavy smoker revealed 50,000 mutations, according ... Nature . , "People in the field have always known ...
... Complete Genomics Inc., a third-generation human genome sequencing company, ... of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), ... sequence and compare a patient,s primary lung tumor and ... to compare the patient,s genome before and after it ...
... treatment of anaplastic thyroid carcinoma has dramatically increased survival in ... say physicians at Mayo Clinic. Their findings will be presented ... Clinical Oncology , to be held June 4-8 in Chicago. ... to aggressively treat metastasis even when this rare cancer seems ...
... ... first Community of Respect™ Medical Center in the Anti-Defamation League’s (ADL’s) Southwest Region. ... ... the first Community of Respect™ Medical Center in the Anti-Defamation League’s (ADL’s) Southwest ...
... ... up to $100,000 per-violation penalties , ... Alexandria, VA (Vocus) May 26, 2010 -- More than ten major ... Network (CEN) offered by the National Association of Chain Drug Stores (NACDS) and RollStream. ...
Cached Medicine News:Health News:Waiting to Clamp the Umbilical Cord May Be Better for Babies 2Health News:Waiting to Clamp the Umbilical Cord May Be Better for Babies 3Health News:Single Lung Tumor Contains 50,000 Mutations 2Health News:Genentech uses Complete Genomics' human genome sequencing service to compare tumor and normal genome in patient with non-small cell lung cancer; results published in Nature 2Health News:New treatment approach to rare cancer results in prolonged survival 2Health News:Houston Northwest Medical Center Becomes First Hospital in the Southwest Region Designated a Community of Respect™ Partner 2Health News:Retailers and Manufacturers Quickly Adopt Online Network to Address CPSIA Compliance 2Health News:Retailers and Manufacturers Quickly Adopt Online Network to Address CPSIA Compliance 3
... protein 4 (IGFBP-4) is a 24 kDa protein ... IGF-I and IGF-II. It is also present in ... 28 kDa. IGFBP-4 has been identified in all ... types, including fibroblasts, neuroblastoma, prostate and bone cells ...
... the adrenal gland and gonads, is the ... both of which may be subsequently converted ... activity, estimated at ~(less than or equal ... androstenedione levels often exceed testosterone in both ...
... Inhibins are heterodimeric proteins that suppress ... from the pituitary. Inhibin consists of two ... linked together. Inhibin A consists of the ... the alpha-subunit and betaB-subunit. Only the dimeric ...
... a 7.5 kDa peptide which is secreted primarily ... mitogenic and metabolic actions involved in cellular growth. ... to target cell receptors. IGF-II binds with high ... monomeric protein which also serves as the receptor ...
Medicine Products: